Novartis News: Novartis Latest News, Novartis Today news, Novartis Breaking News

Novartis India Q1 profit up 16%, revenue climbs 18%; shares fall 3%

Novartis India Q1 profit rose 16% to Rs 32.2 crore and revenue climbed 18%, though shares fell 3%; read the…

July 23, 2026 14:05 IST

Morepen Labs share price surges 16% after Rs 825 crore CDMO order win

Morepen Laboratories share price surged 16% after the company secured a multi-year CDMO order worth Rs 825 crore from a…

February 23, 2026 13:39 IST

Indian public and private sector companies secured major orders this week across energy, infrastructure and engineering.

The Order Book Update: 7 stocks, 7 days, and deals worth Rs 7,000 crore

Indian companies bagged fresh orders this week led by Cochin Shipyard and BHEL, with major wins across shipbuilding, power, renewable…

February 21, 2026 08:30 IST

Novartis AG to exit Novartis India with 70.68% stake sale; open offer announced at Rs 860.64 per share

Novartis AG to sell its entire 70.68% stake in Novartis India for Rs 1,445.89 crore. Buyers including WaveRise Investments and…

February 20, 2026 11:15 IST

From REC-PFC, Swiggy, Ashok Leyland, to Nykaa – Here are 10 stocks to watch

Stocks to watch today, February 20: Track market trends with updates on REC-PFC merger, Swiggy’s Snacc exit, Nykaa’s new partnership,…

February 20, 2026 06:26 IST

New Malaria drug from Novartis could tackle growing drug resistance

Switzerland-based Novartis has developed a new anti-malaria drug, GanLum, that showed 97% effectiveness in late-stage trials. The treatment can help…

November 13, 2025 13:22 IST

Novartis gets USFDA nod for its therapy to treat Berger’s disease

IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular inflammation and…

April 3, 2025 11:19 IST

Novartis’ novel therapy to treat SMA Type 2 shows significant positive outcome in Phase III study

The results from the Phase III STEER study add to the clinical data and emerging real-world evidence for the use…

December 31, 2024 12:58 IST

European Commission gives nod to Novartis’ novel therapy to treat breast cancer

Following recent data announcements at ESMO 20246, Novartis will continue to evaluate NATALEE patients for longer-term outcomes, including overall survival,…

November 27, 2024 16:13 IST

Novartis highlights deep pipeline in core therapeutic areas to drive long-term growth, upgrades mid-term guidance

The company remains on track to deliver core operating income margin of 40%+ by 2027, benefiting from continued strong sales…

November 22, 2024 13:07 IST

Novartis gets positive CHMP opinion for its breast cancer drug to reduce risk of recurrence

According to Novartis, the positive CHMP decision is based on robust data from the Phase III NATALEE trial.

October 18, 2024 18:08 IST

Novartis’ cholesterol-lowering drug shows positive outcome in Phase III trial

Novartis plans to present results from this trial at an upcoming medical meeting and share them with regulatory agencies including…

August 28, 2024 12:39 IST

Novartis releases Phase III data on its investigational oral therapy to treat chronic kidney disease

Atrasentan has the potential to help transform how IgAN is managed for many people living with this complex illness, the…

May 27, 2024 10:58 IST

Novartis to acquire nearly 12 percent stake of MorphoSys AG

Novartis continues to progress the workstreams for implementation of both a delisting of MorphoSys and a domination and profit and…

May 16, 2024 17:34 IST

USFDA gives nod to Novartis’ therapy for rare cancer among children

The study reported a safety profile consistent with the adult population studied in NETTER-1, the pivotal trial for approval of…

April 25, 2024 14:13 IST

Novartis’ Multiple Sclerosis drug is effective for up to six years, study reveals

Multiple Sclerosis is a disease in which the immune system damages the protective covering of nerves. In this condition, nerve…

April 19, 2024 16:02 IST

Novartis releases data of its investigational drug showing positive outcome in Phase 3 trial

Novartis will be presenting further data from the renal portfolio at future medical meetings, it added.

April 16, 2024 13:19 IST

Novartis enters into licensing deal for Arvinas’ cancer drug worth up to $1.01 billion

Under the agreement, Novartis has acquired global rights to develop and commercialize the drug, ARV-766, for an upfront payment of…

April 11, 2024 17:44 IST

Novartis

Related News

Trending Topics